Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Linagliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 20/20 | 1.00 |
| ▸ | FAP | Q12884 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | POU2F2 | P09086 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | POU2F1 | P14859 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | MC4R | P32245 | 1/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 1.00 |
| ▸ | GHSR | Q92847 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Linagliptin SCHEMBL29359185 | 1.00 | DPP4 (1.00) | DPP4FAPCHRM1POU2F2ADORA3 | |
| Linagliptin SCHEMBL28983978 | 1.00 | DPP4 (1.00) | DPP4FAPCHRM1POU2F2ADORA3 | |
| Linagliptin SCHEMBL637238 | 1.00 | DPP4 (1.00) | DPP4FAPCHRM1POU2F2ADORA3 | |
| Linagliptin SCHEMBL17124941 | 1.00 | DPP4 (1.00) | DPP4FAPCHRM1POU2F2ADORA3 | |
| Linagliptin SCHEMBL160188 | 1.00 | DPP4 (1.00) | DPP4FAPCHRM1POU2F2ADORA3 | |
| Linagliptin SCHEMBL16467827 | 0.99 | DPP4 (0.98) | DPP4FAPCHRM1POU2F2ADORA3 | |
| Linagliptin SCHEMBL16467826 | 0.99 | DPP4 (0.98) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL1771688 | 0.93 | DPP4 (0.88) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL1771687 | 0.93 | DPP4 (0.88) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL639186 | 0.93 | DPP4 (0.87) | DPP4FAPCHRM1POU2F2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 612 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312456-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2025-10-09 | — | — | US | claimed |
| US-20250082642-A1 | TREATMENT FOR DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH AN ORAL OR NON-ORAL ANTIDIABETIC DRUG | BOEHRINGER INGELHEIM INT (DE) | 2025-03-13 | — | — | US | claimed |
| EP-4516352-A2 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | Boehringer Ingelheim International GmbH (DE) | 2025-03-05 | — | — | EP | claimed |
| EP-3453403-B1 | DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INT (DE) | 2025-01-22 | — | — | EP | claimed |
| US-20240307403-A1 | DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INT (DE) | 2024-09-19 | — | — | US | claimed |
| US-20240148737-A1 | TREATMENT FOR DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH AN ORAL ANTIDIABETIC DRUG | BOEHRINGER INGELHEIM INT (DE) | 2024-05-09 | — | — | US | claimed |
| US-11919903-B2 | Polymorphs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-03-05 | — | — | US | claimed |
| US-11911388-B2 | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-02-27 | — | — | US | claimed |
| US-20230338386-A1 | DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INT (DE) | 2023-10-26 | — | — | US | claimed |
| EP-4209210-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING BI-1356 AND METFORMIN | Boehringer Ingelheim International GmbH (DE) | 2023-07-12 | — | — | EP | claimed |
| EP-1532149-B1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-12-30 | — | — | EP | claimed |
| WO-2009147125-A1 | DPP-IV INHIBITORS FOR USE IN THE TREATMENT OF NAFLD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | WO | claimed |
| WO-2009121945-A2 | NEW FORMULATIONS, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-08 | — | — | WO | claimed |
| WO-2009022007-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | claimed |
| WO-2009022010-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A SGLT2 INHIBITOR IN COMBINATION WITH A DPP-IV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | claimed |
| WO-2009022008-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | claimed |
| US-20080255159-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2008-10-16 | — | — | US | claimed |
| US-20080249089-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2008-10-09 | — | — | US | claimed |
| US-7407955-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2008-08-05 | — | — | US | claimed |
| US-20070259900-A1 | POLYMORPHS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255159-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | DPP4 2/4885FAP 12/4885CHRM1 993/4885 |
| US-20250082642-A1 | TREATMENT FOR DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH AN ORAL OR NON-ORAL ANTIDIABETIC DRUG | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 238/4885CHRM1 4775/4885 |
| US-20240307403-A1 | DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 27/4885CHRM1 4087/4885 |
| US-11911388-B2 | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 238/4885CHRM1 4775/4885 |
| US-20250312456-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 82/4885CHRM1 4038/4885 |
| US-20240148737-A1 | TREATMENT FOR DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH AN ORAL ANTIDIABETIC DRUG | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 281/4885CHRM1 4748/4885 |
| US-20080249089-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | DPP4 2/4885FAP 12/4885CHRM1 993/4885 |
| US-20230338386-A1 | DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 27/4885CHRM1 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.